Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Appetite and Promotes Weight Loss in Patients With Type 2 Diabetes (T2D): Phase 3 Trial Versus Sitagliptin and Placebo (T-Emerge 4)

被引：0
|
作者：
Bergenstal, Richard
Forti, Adriana
Chiasson, Jean-Louis
Woloschak, Mike
Boldrin, Mark
Leiter, Lawrence
Balena, Raffaella
机构：
来源：
OBESITY | 2010年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [11] Superior glycaemic control with taspoglutide, a once-weekly human GLP-1 analogue, compared with twice daily exenatide in type 2 diabetes: the T-emerge 2 Trial
    Bolli, G. B.
    Rosenstock, J.
    Balas, B.
    Charbonnel, B.
    Boldrin, M.
    Ratner, R.
    Balena, R.
    DIABETOLOGIA, 2010, 53 : S38 - S38
  • [12] Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
    Richard M. Bergenstal
    Adriana Forti
    Jean-Louis Chiasson
    Michael Woloschak
    Mark Boldrin
    Raffaella Balena
    Diabetes Therapy, 2012, 3 (1)
  • [13] Superior Glycemic Control with Taspoglutide, a Once-Weekly Human GLP-1 Analog, Compared with Twice Daily Exenatide in Type 2 Diabetes (T2DM) Inadequately Controlled on Oral Agents: The T-emerge 2 Trial
    Rosenstock, Julio
    Balas, Bogdan
    Charbonnel, Bernard
    Bolli, Geremia B.
    Boldrin, Mark
    Ratner, Robert
    Balena, Raffaella
    DIABETES, 2010, 59 : A17 - A17
  • [14] The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-emerge 2 trial
    Rosenstock, Julio
    Balas, Bogdan
    Charbonnel, Bernard
    Bolli, Geremia B.
    Boldrin, Mark
    Ratner, Robert
    Balena, Raffaella
    DIABETES CARE, 2013, 36 (03) : 498 - 504
  • [15] Taspoglutide, once-weekly human GLP-1 analogue, compared to BID Exenatide improves glucose tolerance and insulin secretion in patients with type 2 diabetes: T-emerge 2 meal tolerance test
    Ratner, R.
    Rosenstock, J.
    Balas, B.
    Charbonnel, B.
    Bolli, G. B.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [16] Taspoglutide, a Once-Weekly Human GLP-1Analog, Improves Glucose Tolerance and Insulin Secretion in Patients with Type 2 Diabetes (T2DM): Results of a Meal Tolerance Test from T-emerge 2
    Rosenstock, Julio
    Balas, Bogdan
    Charbonnel, Bernard
    Bolli, Geremia B.
    Boldrin, Mark N.
    Ratner, Robert
    Balena, Raffaella
    DIABETES, 2010, 59 : A196 - A196
  • [17] Effect of Taspoglutide, a Human GLP-1 Analog, on Insulin Secretion in Patients (pts) with Type 2 Diabetes (T2D)
    Pellanda, Carolina
    Mangold, Bernhard
    Schulte, Michael
    Niggli, Markus
    Kapitza, Christoph
    DIABETES, 2010, 59 : A160 - A161
  • [18] Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
    Kapitza, C.
    Heise, T.
    Birman, P.
    Jallet, K.
    Ramis, J.
    Balena, R.
    DIABETIC MEDICINE, 2009, 26 (11) : 1156 - 1164
  • [19] Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
    Leiter, Lawrence A.
    Carr, Molly C.
    Stewart, Murray
    Jones-Leone, Angela
    Scott, Rhona
    Yang, Fred
    Handelsman, Yehuda
    DIABETES CARE, 2014, 37 (10) : 2723 - 2730
  • [20] A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
    Nauck, Michael A.
    Petrie, John R.
    Sesti, Giorgio
    Mannucci, Edoardo
    Courreges, Jean-Pierre
    Lindegaard, Marie L.
    Jensen, Christine B.
    Atkin, Stephen L.
    DIABETES CARE, 2016, 39 (02) : 231 - 241
12345